Treatment Algorithm for Relapsed/Refractory DLBCL

August 15, 2024

By Rahul Gosain, MD
Rohit Gosain, MD

Opinion

Video

Carla Casulo, MD, and the Oncology Brothers review the treatment algorithm for patients with relapsed/refractory DLBCL.

EP: 1.Biopsy Practices in DLBCL

EP: 2.First-Line Treatment of Stage I/II DLBCL

EP: 3.Treatment Practices for Stage III/IV DLBCL

Now Viewing

EP: 4.Treatment Algorithm for Relapsed/Refractory DLBCL

EP: 5.Adverse Event Considerations in DLBCL

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Recent Videos

Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.

Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.

$Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.$

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777